Sio Gene Therapies (SIOX) – Research Analysts’ Weekly Ratings Updates

Several analysts have recently updated their ratings and price targets for Sio Gene Therapies (NASDAQ: SIOX):

  • 7/20/2021 – Sio Gene Therapies was upgraded by analysts at Zacks Investment Research from a “hold” rating to a “buy” rating. They now have a $2.50 price target on the stock. According to Zacks, “Axovant Sciences Ltd. is a biopharmaceutical company which focuses on the acquisition, development and commercialization of therapeutics for the treatment of neurodegenerative disorders. Its product candidate includes RVT-101 which is in different clinical trial for the treatment of Alzheimer’s disease and other forms of dementia. Axovant Sciences Ltd. is based in Hamilton, Bermuda. “
  • 7/17/2021 – Sio Gene Therapies was downgraded by analysts at Zacks Investment Research from a “buy” rating to a “hold” rating. According to Zacks, “Axovant Sciences Ltd. is a biopharmaceutical company which focuses on the acquisition, development and commercialization of therapeutics for the treatment of neurodegenerative disorders. Its product candidate includes RVT-101 which is in different clinical trial for the treatment of Alzheimer’s disease and other forms of dementia. Axovant Sciences Ltd. is based in Hamilton, Bermuda. “
  • 7/14/2021 – Sio Gene Therapies was upgraded by analysts at Zacks Investment Research from a “hold” rating to a “buy” rating. They now have a $2.75 price target on the stock. According to Zacks, “Axovant Sciences Ltd. is a biopharmaceutical company which focuses on the acquisition, development and commercialization of therapeutics for the treatment of neurodegenerative disorders. Its product candidate includes RVT-101 which is in different clinical trial for the treatment of Alzheimer’s disease and other forms of dementia. Axovant Sciences Ltd. is based in Hamilton, Bermuda. “
  • 7/8/2021 – Sio Gene Therapies was downgraded by analysts at Zacks Investment Research from a “buy” rating to a “hold” rating. According to Zacks, “Axovant Sciences Ltd. is a biopharmaceutical company which focuses on the acquisition, development and commercialization of therapeutics for the treatment of neurodegenerative disorders. Its product candidate includes RVT-101 which is in different clinical trial for the treatment of Alzheimer’s disease and other forms of dementia. Axovant Sciences Ltd. is based in Hamilton, Bermuda. “
  • 7/7/2021 – Sio Gene Therapies had its “buy” rating reaffirmed by analysts at Chardan Capital.
  • 7/6/2021 – Sio Gene Therapies was upgraded by analysts at Zacks Investment Research from a “hold” rating to a “buy” rating. They now have a $3.00 price target on the stock. According to Zacks, “Axovant Sciences Ltd. is a biopharmaceutical company which focuses on the acquisition, development and commercialization of therapeutics for the treatment of neurodegenerative disorders. Its product candidate includes RVT-101 which is in different clinical trial for the treatment of Alzheimer’s disease and other forms of dementia. Axovant Sciences Ltd. is based in Hamilton, Bermuda. “
  • 7/1/2021 – Sio Gene Therapies had its “buy” rating reaffirmed by analysts at Chardan Capital.
  • 6/14/2021 – Sio Gene Therapies is now covered by analysts at BTIG Research. They set a “buy” rating and a $8.00 price target on the stock.
  • 6/13/2021 – Sio Gene Therapies had its “buy” rating reaffirmed by analysts at Robert W. Baird. They now have a $7.00 price target on the stock.
  • 6/9/2021 – Sio Gene Therapies had its “buy” rating reaffirmed by analysts at HC Wainwright. They now have a $8.00 price target on the stock.

SIOX stock traded down $0.10 during trading on Thursday, reaching $2.30. 12,301 shares of the company’s stock were exchanged. Sio Gene Therapies Inc. has a 1-year low of $1.86 and a 1-year high of $5.74. The company has a fifty day simple moving average of $2.42. The stock has a market capitalization of $108.68 million and a price-to-earnings ratio of -2.74.

Sio Gene Therapies (NASDAQ:SIOX) last announced its quarterly earnings results on Tuesday, June 8th. The company reported ($0.05) earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of ($0.22) by $0.17. On average, equities research analysts forecast that Sio Gene Therapies Inc. will post -0.71 EPS for the current year.

Institutional investors have recently made changes to their positions in the company. XTX Topco Ltd acquired a new position in Sio Gene Therapies during the first quarter valued at $28,000. Jane Street Group LLC acquired a new position in Sio Gene Therapies during the fourth quarter valued at $32,000. New York Life Investments Alternatives acquired a new position in Sio Gene Therapies during the first quarter valued at $41,000. ExodusPoint Capital Management LP acquired a new position in Sio Gene Therapies during the fourth quarter valued at $88,000. Finally, Dimensional Fund Advisors LP acquired a new position in Sio Gene Therapies during the fourth quarter valued at $93,000. Institutional investors and hedge funds own 0.02% of the company’s stock.

Sio Gene Therapies, Inc, a clinical-stage company, focuses on developing gene therapies to radically transform the lives of patients with neurodegenerative diseases. The company develops AXO-Lenti-PD, in vivo lentiviral gene therapy, which is in Phase II clinical trials for the treatment of Parkinson's disease; AXO-AAV-GM1, an investigational gene therapy , which is in Phase I/II clinical trials for the treatment of GM1 gangliosidosis; and AXO-AAV-GM2, an investigational gene therapy, which is in Phase I/II clinical trials for the treatment of GM2 gangliosidosis.

Recommended Story: Consumer Price Index (CPI)

Receive News & Ratings for Sio Gene Therapies Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sio Gene Therapies Inc and related companies with MarketBeat.com's FREE daily email newsletter.